Vol 24, No 2 (2017)
Original articles — Basic science and experimental cardiology
Published online: 2016-10-17

open access

Page views 3387
Article views/downloads 2730
Get Citation

Connect on Social Media

Connect on Social Media

Preliminary study of beta-blocker therapy on modulation of interleukin-33/ST2 signaling during ventricular remodeling after acute myocardial infarction

Jinggang Xia, Yang Qu, Chunlin Yin, Dong Xu
Pubmed: 27748502
Cardiol J 2017;24(2):188-194.


Background: This study aimed to evaluate the role of b-blocker therapy on modulating interleukin (IL)-33/ST2 (interleukin-1 receptor-like 1) signaling during ventricular remodeling related to heart failure (HF) after acute myocardial infarction (AMI).

Methods: Sprague-Dawley rats that survived surgery to induce AMI were randomly divided into the placebo group and the b-blocker treatment group. A sham group was used as a control. Left ventricular (LV) function variables, the myocardial infarct size, fibrosis and IL-33/ST2 protein expression was measured.

Results: Compared with the placebo group, b-blocker treatment significantly improved LV function and reduced infarct size (p < 0.05). There was higher protein expression of IL-33 (p < 0.05) and sST2 (p < 0.05), as well as higher expression of fibrosis (p < 0.05), compared to the sham group. Notably, the high expression of cardioprotective IL-33 was not affected by b-blocker treatment (p > 0.05), however, treatment with b-blocker enhanced IL-33/ST2 signaling, with lower expression of sST2 (p < 0.05) and significantly attenuated fibrosis (p < 0.05).

Conclusions: Our study suggested that b-blocker therapy might play a beneficial role in the modula­tion of IL-33/ST2 signaling during ventricular remodeling. These results may be helpful in identifying IL-33/ST2 systems as putative b-blocker targets at an early stage after AMI. (Cardiol J 2017; 24, 2: 188–194)

Article available in PDF format

View PDF Download PDF file


  1. Hunt SA, Abraham WT, Chin MH, et al. American College of Cardiology Foundation, American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009; 53(15): e1–e90.
  2. Sharma S, Colangelo LA, Lima J, et al. Effects of Weight and Weight Change on Cardiac Remodeling Over 20 Years: The CARDIA (Coronary Artery Risk Development in Young Adults) Study. J Am Coll Cardiol. 2015; 65(22): 2463–2465.
  3. Cole GD, Patel SJ, Zaman N, et al. "Triple therapy" of heart failure with angiotensin-converting enzyme inhibitor, beta-blocker, and aldosterone antagonist may triple survival time: shouldn't we tell patients? JACC Heart Fail. 2014; 2(5): 545–548.
  4. Fukui M, Goda A, Komamura K, et al. Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure. Heart Vessels. 2016; 31(2): 173–182.
  5. Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta. 2015; 443: 57–70.
  6. Miller AM, Liew FY. The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease. Pharmacol Ther. 2011; 131(2): 179–186.
  7. Yin H, Li P, Hu F, et al. IL-33 attenuates cardiac remodeling following myocardial infarction via inhibition of the p38 MAPK and NF-κB pathways. Mol Med Rep. 2014; 9(5): 1834–1838.
  8. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011; 8(1): 22.
  9. Bayes-Genis A, de Antonio M, Galán A, et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail. 2012; 14(1): 32–38.
  10. Liu Mi, Wang XR, Wang C, et al. Panax quinquefolium saponin attenuates ventricular remodeling after acute myocardial infarction by inhibiting chop-mediated apoptosis. Shock. 2013; 40(4): 339–344.
  11. Lax A, Sanchez-Mas J, Asensio-Lopez MC, et al. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. JACC Heart Fail. 2015; 3(1): 50–58.
  12. Sánchez-Más J, Lax A, Asensio-López MD, et al. Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. Eur J Clin Invest. 2014; 44(7): 643–651.
  13. Litwin SE, Katz SE, Morgan JP, et al. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation. 1994; 89(1): 345–354.
  14. Xia Jg, Xu Ff, Qu Y, et al. Atorvastatin post-conditioning attenuates myocardial ischemia reperfusion injury via inhibiting endoplasmic reticulum stress-related apoptosis. Shock. 2014; 42(4): 365–371.
  15. Wolfrum S, Dendorfer A, Schutt M, et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol. 2004; 44(3): 348–355.
  16. Armstrong C. ACCF and AHA Release Guidelines on the Management of Heart Failure. Am Fam Physician. 2014; 90(3): 186–189.
  17. Mair J, Jaffe A, Apple F, et al. Cardiac biomarkers. Dis Markers. 2015; 2015: 370569.
  18. Daniels LB, Bayes-Genis A. Using ST2 in cardiovascular patients: a review. Future Cardiol. 2014; 10(4): 525–539.
  19. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16): 1810–1852.
  20. Gaggin HK, Motiwala S, Bhardwaj A, et al. Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Circ Heart Fail. 2013; 6(6): 1206–1213.
  21. Chatterjee S, Udell JA, Sardar P, et al. Comparable benefit of β-blocker therapy in heart failure across regions of the world: meta-analysis of randomized clinical trials. Can J Cardiol. 2014; 30(8): 898–903.
  22. Wikstrand J, Wedel H, Castagno D, et al. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Intern Med. 2014; 275(2): 134–143.
  23. Breidthardt T, Balmelli C, Twerenbold R, et al. Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J Card Fail. 2013; 19(12): 821–828.
  24. Nguyen T, Shaheed A, Venigalla S, et al. Using beta-blockers to treat heart failure. JAAPA. 2014; 27(12): 50–55.
  25. Prijic S, Buchhorn R. Mechanisms of Beta-Blockers Action in Patients with Heart Failure. Rev Recent Clin Trials. 2014; 9(2): 58–60.
  26. Bølling R, Scheller NM, Køber L, et al. Comparison of the clinical outcome of different beta-blockers in heart failure patients: a retrospective nationwide cohort study. Eur J Heart Fail. 2014; 16(6): 678–684.